🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Pharmacokinetic Study of Tranexamic Acid

RecruitingNAAges 20 Years - 64 YearsFemaleZhejiang Cancer Hospital
NCT06728670 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Tranexamic acid is an effective anti fibrinolytic drug. Clinical studies have found that intravenous injection of tranexamic acid is more effective in reducing blood loss and transfusion in patients with advanced ovarian cancer, without increasing the risk of postoperative complications. Different surgeries and administration routes have an impact on the pharmacokinetics and pharmacodynamics of TXA. At present, there is little data on the pharmacokinetics of intramuscular injection of TXA, and almost all of the data comes from males. For ovarian cancer patients, there are currently no reports on the pharmacokinetics of TXA through different routes of administration, such as intramuscular and intravenous administration. Therefore, the investigators chose ovarian cancer patients and administered it through different routes of intravenous and intramuscular injection.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Adult women aged 20-64 diagnosed with advanced ovarian cancer undergoing cytoreductive surgery 2. The cancer stage is III-IV 3. ASA classification II-III 4. Surgical duration\>2 hours Exclusion Criteria: 1. Renal dysfunction (serum creatinine\>200 mmol/L) or liver dysfunction (Child Turcote classification\>6) 2. Has a history of serious mental illness or disorders, epilepsy, visual impairment 3. Previous or current bleeding disorders, coagulation dysfunction, or thromboembolic events 4. Lower limb venous thrombosis 5. Anticoagulants or antifibrinolytic drugs used before surgery within the past month 6. Allergic to TXA
💊

What it tests

  • Tranexamic acid Intravenous Infusion
  • TXA intramuscular injection
📍

Where

1 site
Zhejiang Cancer Hospital
Hangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy